ALFA Finder| Revenue growth | 17.3% FY26 YoY growth; 20.2% in Q4FY26. |
|---|---|
| Margins | EBITDA margin improved 85bps to 20.9% in FY26. |
| Demand visibility | Strong, driven by chronic therapies contributing 71.9% revenue. |
| Management confidence | High, citing brand strength and execution excellence. |
Growth
FY26 Revenue up 17.3%, Adjusted PAT up 33.4% to ₹199.4 Cr. Q4FY26 revenue grew 20.2% YoY.
Outlook
Targets expanding into nephrology, CNS, and dermatology. Capacity added for 400 Mn units; entering EAEU markets.
Risks
Exposure to market risks, technological implementation changes, and potential impact of New Labor Code regulations.
Earnings Call filed with NSE, NSE: CORONA. Summary written with AI assistance from the document.
Corona Remedies Ltd: key numbers
- Share price
- ₹2,387.30
- Market cap
- ₹14,601 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 70.5×Sector 43.8×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 4.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Corona Remedies Ltd
All →Corona Remedies Legal & Regulatory
Corona Remedies received an NPPA demand notice of Rs 4.88 Crore for alleged DPCO 2013 price violations. The company is evaluating it and reports no material financial impact.
- Value
- ₹4.88 Cr
Corona Remedies Earnings Call Transcript: Key Takeaways
CORONA delivered robust revenue growth of 22% YoY, outperforming the Indian pharmaceutical market by focusing on chronic segments. Management maintains a growth target of 1.5x the market rate.
- Call
- Guides 15% growth
Corona Remedies Investor Presentation: Key Takeaways
Q2FY27 revenue ₹441.2Cr (+22.2%), PAT ₹60.3Cr (+15.3%); H1 revenue ₹863.6Cr (+22.0%), PAT ₹120.4Cr (+22.2%). Chronic-led growth, outpacing IPM.
Corona Remedies Results Update
Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.
Corona Remedies Q2 FY27 Results: Net Profit ₹60.3 Cr, Up 15.3% YoY
Corona Remedies Ltd reported revenue from operations of ₹441.2 Cr (+22.2% YoY) and net profit of ₹60.3 Cr (+15.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹60.3 Cr · +15.3% YoY
Corona Remedies Business Update
Corona Remedies received GMP Compliance Certification from Brazil's ANVISA for its OSD and Hormone facilities in Ahmedabad. This validates export eligibility to the Brazilian pharmaceutical market.